SAN FRANCISCO & LONDON--(BUSINESS WIRE)--Aiolos Bio, Inc. (“Aiolos” or “the Company”) today announced its launch as a clinical-stage biopharmaceutical company focused on addressing the unmet treatment ...
Upstream Bio is presenting at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025, which highlights the company's commitment to disseminating important research and gaining ...
– Pharmacology modeling data presented at the European Academy of Allergy & Clinical Immunology (EAACI) Congress describe mechanistic insights for greater potency with verekitug compared to ...
Please provide your email address to receive an email when new articles are posted on . Patients with asthma saw a 23% reduction in FeNO with treatment. Most adverse events were mild, with no serious ...
NEWARK, Del. and NANJING, China, June 11, 2024 /PRNewswire/ -- Biosion, a global, clinical-stage biotechnology company, today presented key results from the ADAMANT study, a phase 2 proof-of-concept ...
Upstream Bio's sole drug, verekitug, targets severe asthma, CRSwNP, and COPD, with promising early phase 2 data expected in 2025 and 2026. Verekitug, a TSLP receptor inhibitor, shows higher efficacy ...
– Global Phase 2 clinical trial, VENTURE, to evaluate the efficacy and safety of verekitug administered every 12 or 24 weeks in moderate-to-severe COPD – – Broadens global development program for ...
Phase 2 POLARIS trial will evaluate the dosing, safety, and efficacy of WIN378 in patients with asthma, with a first data readout expected in mid-2026 WIN378 has the potential to be the ...
Treating obese mice with the cytokine known as TSLP led to significant abdominal fat and weight loss compared to controls. The animal model findings support the possibility that increasing sebum ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results